|
1
|
Harada H: How can we overcome tumor
hypoxia in radiation therapy? J Radiat Res. 52:545–556. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brown JM: Tumor hypoxia in cancer therapy.
Methods Enzymol. 435:297–321. 2007.PubMed/NCBI
|
|
3
|
Horsman MR, Lindegaard JC, Grau C,
Nordsmark M, Alsner J and Overgaard J: Chapter 3-dose-response
modifiers in radiation therapy A2-gunderson, leonard LClinical
radiation oncology. Tepper JE: 4th. Elsevier; Philadelphia, PA: pp.
51–62. 2016, View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaanders JH, Bussink J and van der Kogel
AJ: Clinical studies of hypoxia modification in radiotherapy. Semin
Radiat Oncol. 14:233–240. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Overgaard J, Eriksen JG, Nordsmark M,
Alsner J and Horsman MR; Danish Head and Neck Cancer Study Group, :
Plasma osteopontin, hypoxia and response to the hypoxia sensitiser
nimorazole in radiotherapy of head and neck cancer: Results from
the DAHANCA 5 randomised double-blind placebo-controlled trial.
Lancet Oncol. 6:757–764. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Overgaard J, Hansen HS, Overgaard M,
Bastholt L, Berthelsen A, Specht L, Lindeløv B and Jørgensen K: A
randomized double-blind phase III study of nimorazole as a hypoxic
radiosensitizer of primary radiotherapy in supraglottic larynx and
pharynx carcinoma. Results of the Danish Head and Neck Cancer Study
(DAHANCA) Protocol 5–85. Radiother Oncol. 46:135–146. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oya N, Shibamoto Y, Sasai K, Shibata T,
Murata R, Takagi T, Iwai H, Suzuki T and Abe M: Optical isomers of
a new 2-nitroimidazole nucleoside analog (PR-350 series):
Radiosensitization efficiency and toxicity. Int J Radiat Oncol Biol
Phys. 33:119–127. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shibamoto Y, Kubota T, Kishii K and
Tsujitani M: Radiosensitivity of human pancreatic cancer cells in
vitro and in vivo and the effect of a new hypoxic cell sensitizer,
doranidazole. Radiother Oncol. 56:265–270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yahiro T, Masui S, Kubota N, Yamada K,
Kobayashi A and Kishii K: Effects of hypoxic cell radiosensitizer
doranidazole (PR-350) on the radioresponse of murine and human
tumor cells in vitro and in vivo. J Radiat Res. 46:363–372. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang L, Gong A, Ji J, Wu Y, Zhu X, Lv S,
Lv H and Sun X: The radiosensitizing effect of doranidazole on
human colorectal cancer cells exposed to high doses of irradiation.
BMC cancer. 7:1882007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsuoka H, Shibamoto Y, Kubota T,
Tsujitani M and Majima T: In vivo efficacy and pharmacokinetics of
a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human
pancreatic cancer xenografted in mouse pancreas. Oncol Rep.
7:23–26. 2000.PubMed/NCBI
|
|
12
|
Murata R, Tsujitani M and Horsman MR:
Enhanced local tumour control after single or fractionated
radiation treatment using the hypoxic cell radiosensitizer
doranidazole. Radiother Oncol. 87:331–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yasui H, Asanuma T, Kino J, Yamamori T,
Meike S, Nagane M, Kubota N, Kuwabara M and Inanami O: The
prospective application of a hypoxic radiosensitizer, doranidazole
to rat intracranial glioblastoma with blood brain barrier
disruption. BMC Cancer. 13:1062013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishimura Y, Nakagawa K, Takeda K, Tanaka
M, Segawa Y, Tsujino K, Negoro S, Fuwa N, Hida T, Kawahara M, et
al: Phase I/II trial of sequential chemoradiotherapy using a novel
hypoxic cell radiosensitizer, doranidazole (PR-350), in patients
with locally advanced non-small-cell lung Cancer (WJTOG-0002). Int
J Radiat Oncol Biol Phys. 69:786–792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karasawa K, Sunamura M, Okamoto A, Nemoto
K, Matsuno S, Nishimura Y and Shibamoto Y: Efficacy of novel
hypoxic cell sensitiser doranidazole in the treatment of locally
advanced pancreatic cancer: Long-term results of a
placebo-controlled randomised study. Radiother Oncol. 87:326–330.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sunamura M, Karasawa K, Okamoto A, Ogata
Y, Nemoto K, Hosotani R, Nishimura Y, Matsui K and Matsuno S;
PR-350 Study Group, : Phase III trial of radiosensitizer PR-350
combined with intraoperative radiotherapy for the treatment of
locally advanced pancreatic cancer. Pancreas. 28:330–334. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng YC, Wu R, Xu ZG, Zhang XY, Fan GL, Wu
LN, Wang YM, Hao SH, Zheng W, Chen XD, et al: Safety and
radiation-enhancing effect of sodium glycididazole in
locoregionally advanced laryngeal cancers previously treated with
platinum-containing chemotherapy regimens: A preliminary report.
Cancer Radiother. 14:59–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li MY, Liu JQ, Chen DP, Qi B, Liang YY and
Yin WJ: Glycididazole sodium combined with radiochemotherapy for
locally advanced nasopharyngeal carcinoma. Asian Pac J Cancer Prev.
15:2641–2646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zeng YC, Wu R, Xing R, Chi F, Wang SL,
Chen XD, Xuan Y, Wu LN, Duan QY, Tang MY, et al:
Radiation-enhancing effect of sodium glycididazole in patients
suffering from non-small cell lung cancer with multiple brain
metastases: A randomized, placebo-controlled study. Cancer
Radiother. 20:187–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng YC, Xing R, Zeng J, Xue M, Chi F, Xin
Y, Fan GL, Wang HM, Duan QY, Sun YN, et al: Sodium glycididazole
enhances the radiosensitivity of laryngeal cancer cells through
downregulation of ATM signaling pathway. Tumour Biol. 37:5869–5878.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mahfouz NM and Hassan MA: Synthesis,
chemical and enzymatic hydrolysis and bioavailability evaluation in
rabbits of metronidazole amino acid ester prodrugs with enhanced
water solubility. J Pharm Pharmacol. 53:841–848. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alestig K, Freij L and Arnold E:
Absorption and excretion of metronidazole after administration of
metronidazole benzoate mixture. Scand J Infect Dis. 12:149–152.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mathew M, Das Gupta V and Bethea C:
Stability of metronidazole benzoate in suspensions. J Clin Pharm
Ther. 19:31–34. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mahfouz NM, Aboul-Fadl T and Diab AK:
Metronidazole twin ester prodrugs: Synthesis, physicochemical
properties, hydrolysis kinetics and antigiardial activity. Eur J
Med Chem. 33:675–683. 1998. View Article : Google Scholar
|
|
25
|
Urtasun R, Feldstein ML, Partington J,
Tanasichuk H, Miller JD, Russell DB, Agboola O and Mielke B:
Radiation and nitroimidazoles in supratentorial high grade gliomas:
A second clinical trial. Br J Cancer. 46:101–108. 1982. View Article : Google Scholar : PubMed/NCBI
|
